The World Anti-Doping Agency (WADA) today announces the publication of the following revised Technical Documents for 2022, along with summaries of the amendments. These Technical Documents were approved by the WADA Executive Committee on October 6, 2021, following a postal vote.
By virtue of International Standard for Laboratories (SIL), WADA Technical Documents are published to provide guidance to WADA-accredited laboratories, WADA-approved Athlete Biological Passport laboratories, and other stakeholders, on technical matters or specific procedures. As part of its ongoing efforts to strengthen anti-doping activities under the World Anti-Doping Code, WADA periodically reviews the Technical Documents to reflect scientific and technological advances in doping control and reporting. . These documents are reviewed and amended in consultation with WADA's partners.
TECHNICAL DOCUMENTS 2022
Please note that all WADA accredited laboratories are required to implement the following Technical Documents in their procedures by the 1er January 2022 :
- TD2022EPO : This Technical Document concerns the harmonization of the analysis and rendering of erythropoietin (EPO) and other erythropoietin receptor agonists (ERA) by methods of analysis by polyacrylamide gel electrophoresis (PAGE ). It replaces the current TD2021EPO v2.0. This new version of the Technical Document includes an appendix B, which describes the existence of a minor variant of the EPO gene present in a minimal percentage (<1%) of people of East Asian descent and provides additional guidance. for the management and reporting of recombinant EPO (recEPO) results.
- TD2022MRPL : This Technical Document concerns the minimum required performance levels (NMPR) and minimum reporting levels (NMR) applicable to non-threshold substances analyzed by methods of analysis by chromatography and mass spectrometry. It replaces the current TD2019MRPL. In this new version of the Technical Document, important changes have been incorporated, including:
- the concept of NMR for certain non-threshold substances;
- the difference between NMPR and NMR;
- adjusting the concentrations of the target analyte (s) for non-threshold substances with an NMR of specific gravity> 1,018;
- the requirements for reporting an Adverse Analytical Finding (AAR) have been revised for non-threshold substances subject to an NMR, including the use of an internal standard, a single point calibrator at 120% of the NMR and a quality control sample at the NMR concentration;
- the definition of new NRMs for certain substances (e.g. growth promoters (in accordance with WADA Technical Letter 23); certain diuretics / contaminants (in accordance with WADA Technical Letter 24); vilanterol (a beta-2 agonist); dextran, mannitol and probenecid (masking agents); the parent compound of cocaine; and some glucocorticoids).
- TD2022DL : This Technical Document concerns the decision limits for the confirmatory quantification of exogenous threshold substances by analytical methods based on chromatography. It replaces the current TD2021DL. This new version of the Technical Document has been modified to align it with the TD2022MRPL with respect to the reporting of results for threshold substances (i.e. salbutamol, formoterol, cathine, ephedrine, methylephedrine and pseudoephedrine) when detected together with a diuretic subjected to a NMR, or in the presence of any other diuretic or masking agent. Further clarifications are provided in cases where there is an approved therapeutic use authorization for the diuretic and / or threshold substance. In addition, it was clarified that, for cathine, the threshold of 5,00 μg / mL and the decision limit of 6,00 μg / mL are applicable to cathine and its l-enantiomer.
- TD2022IRMS : This Technical Document covers the detection of synthetic forms of prohibited substances by gas chromatography isotope ratio mass spectrometry (GC / C / IRMS). It replaces the current TD2021IRMS v2.0. In this new version of the Technical Document, prednisone and prednisolone have been deleted as target compounds for analysis by GC / C / IRMS. This decision follows the revised and higher MLRs defined for these two glucocorticoids in the TD2022MRPL, which make CG / C / IRMS analysis unnecessary for reporting AARs at levels above the NMR. In addition, further clarification is provided on the use of secondary endogenous reference compounds.
All Technical documents mentioned above are available and indexed on the WADA website.
If you have any questions or comments, please do not hesitate to contact WADA's Science Department at science@wada-ama.org.
